Morgan Stanley Bio Atla, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Bio Atla, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,858,176 shares of BCAB stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,858,176

Previous 1,854,768 0.18%

Holding current value

$1.28 Million

Previous $2.54 Million 28.69%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.17 - $2.05 $3,987 - $6,986	3,408 Added 0.18%	1,858,176 $3.27 Million
Q2 2024 Oct 17, 2024	SELL	$1.37 - $3.92 $75,865 - $217,073	-55,376 Reduced 2.9%	1,854,768 $2.54 Million
Q2 2024 Aug 14, 2024	SELL	$1.37 - $3.92 $75,865 - $217,073	-55,376 Reduced 2.9%	1,854,768 $2.54 Million
Q1 2024 Oct 17, 2024	BUY	$1.88 - $3.46 $104,106 - $191,600	55,376 Added 2.99%	1,910,144 $6.57 Million
Q1 2024 Aug 16, 2024	SELL	$1.88 - $3.46 $5,585 - $10,279	-2,971 Reduced 0.16%	1,910,144 $6.57 Million
Q1 2024 May 15, 2024	SELL	$1.88 - $3.46 $5,585 - $10,279	-2,971 Reduced 0.16%	1,910,144 $6.57 Million
Q4 2023 Aug 16, 2024	BUY	$1.27 - $3.18 $74,100 - $185,543	58,347 Added 3.15%	1,913,115 $4.71 Million
Q4 2023 Feb 13, 2024	BUY	$1.27 - $3.18 $396,655 - $993,199	312,327 Added 19.51%	1,913,115 $4.71 Million
Q3 2023 Nov 15, 2023	SELL	$1.7 - $3.07 $154,871 - $279,680	-91,101 Reduced 5.38%	1,600,788 $2.72 Million
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $528,168 - $722,265	-186,632 Reduced 9.94%	1,691,889 $5.08 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $131,461 - $471,545	57,157 Added 3.14%	1,878,521 $5.03 Million
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $1.09 Million - $1.91 Million	173,600 Added 10.54%	1,821,364 $15 Million
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $1.67 Million - $6.75 Million	568,986 Added 52.74%	1,647,764 $12.7 Million
Q2 2022 Oct 27, 2022	SELL	$2.13 - $5.38 $1.1 Million - $2.77 Million	-515,213 Reduced 32.32%	1,078,778 $3.08 Million
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $1.1 Million - $2.77 Million	-515,213 Reduced 32.32%	1,078,778 $3.08 Million
Q1 2022 Oct 27, 2022	BUY	$4.38 - $18.78 $2.26 Million - $9.68 Million	515,213 Added 47.76%	1,593,991 $7.97 Million
Q1 2022 May 13, 2022	BUY	$4.38 - $18.78 $4.09 Million - $17.5 Million	933,752 Added 141.43%	1,593,991 $7.97 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $8.1 Million - $13.2 Million	426,454 Added 182.41%	660,239 $13 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $6.88 Million - $10.2 Million	233,785 New	233,785 $6.88 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.4M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $25M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account